FARMINGDALE, N.Y., Aug. 23, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, received a positive reception to the BoneScalpel's ultrasonic technology from more than 60 oral-maxillofacial surgeons attending the Taiwan Association of Maxillofacial Surgeons Forum on Contemporary Facial Skeletal Surgery held in Hualien, Taiwan on August 16-17.
Michael Y. Chen, Chief and Assistant Professor, Dental Department and Division of Oral and Maxillofacial Surgery, Taichung China Medical University Hospital and Executive Director of the Taiwan Association of Oral and Maxillofacial Surgeons, presented on his technique for performing sagittal split ramus osteotomy using the BoneScalpel ultrasonic bone-cutter. Dr. Chen has performed more than 100 bilateral sagittal split ramus osteotomies using the BoneScalpel and has found the enhanced safety against nerve injury and the high level of precision to be major benefits. "The nerve-sparing nature of ultrasonic bone-cutting technology is very valuable in performing certain maxillofacial surgeries where nerve damage is a risk," said Dr. Chen. "The BoneScalpel also allows for very fast and precise cuts making it ideal for oral and maxillofacial surgery."
The second day of the conference included a hands-on cadaver workshop where more than 60 surgeons learned various advanced surgical techniques using the BoneScalpel. The cadaveric workshop was held at the Medical Simulation Center of the Tzu-Chi University in Hualien.
Grand Medical, the Misonix distributor in Taiwan, has found that Taiwanese spine surgeons have enthusiastically embraced the BoneScalpel which is now used in the majority of major medical centers in Taiwan. Grand Medical has recently begun introducing the BoneScalpel to maxillofacial surgeons in Taiwan where its clinical benefits are also finding widespread appreciation. "We have found BoneScalpel to be very popular with spine surgeons in Taiwan and we think that maxillofacial surgeons will also find BoneScalpel to be a very useful technology. The excellent results from Dr. Chen's first 100 patients are very encouraging. We think that there is a high potential for BoneScalpel in oral and maxillofacial surgery in Taiwan," stated Jackey Wu, CEO, Grand Medical.
Commenting further, Scott Ludecker, Senior Vice President of Global Sales and Marketing stated, "Misonix will continue to invest in workshops around the world where surgeons can experience for themselves, the versatility, safety, and effectiveness of our technologies. Our distributor, Grand Medical, has done an outstanding job introducing BoneScalpel into the spine surgery marketplace and we are very encouraged by the interest shown by the oral and maxillofacial surgeons this past week in Taiwan."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.